Treatment with the uPARAP ADC had a pronounced antitumor effect, including an initial tumor regression (around d15-d18 after first treatment) and a further delayed growth relative to the three control groups [Fig. 6A (left); individual tumor volume data shown in Supplementary Fig. S7]. The gene discussed is MRC2; the disease is neoplasm.